Lung cancer is an attractive context for current programmed cell death-1 (PD-1) and its ligand PD-L1 and Cytotoxic-T-lymphocyte-antigen-4 (CTLA-4) therapy due to its enhanced neo-antigen expression levels and ability to aid tumor cells in evading immune surveillance. The gene discussed is PDCD1; the disease is lung carcinoma.